{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:16:37Z","timestamp":1762431397800},"reference-count":70,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,7]]},"abstract":"<jats:p>Yellow fever (YF) is a viral disease transmitted by mosquitoes and endemic mostly in South America and Africa with 20\u201350% fatality. All current licensed YF vaccines, including YF-Vax<jats:sup>\u00ae<\/jats:sup> (Sanofi-Pasteur, Lyon, France) and 17DD-YFV (Bio-Manguinhos, Rio de Janeiro, Brazil), are based on live attenuated virus produced in hens\u2019 eggs and have been widely used. The YF vaccines are considered safe and highly effective. However, a recent increase in demand for YF vaccines and reports of rare cases of YF vaccine-associated fatal adverse events have provoked interest in developing a safer YF vaccine that can be easily scaled up to meet this increased global demand. To this point, we have engineered the YF virus envelope protein (YFE) and transiently expressed it in <jats:italic>Nicotiana benthamiana<\/jats:italic> as a stand-alone protein (YFE) or as fusion to the bacterial enzyme lichenase (YFE-LicKM). Immunogenicity and challenge studies in mice demonstrated that both YFE and YFE-LicKM elicited virus neutralizing (VN) antibodies and protected over 70% of mice from lethal challenge infection. Furthermore, these two YFE-based vaccine candidates induced VN antibody responses with high serum avidity in nonhuman primates and these VN antibody responses were further enhanced after challenge infection with the 17DD strain of YF virus. These results demonstrate partial protective efficacy in mice of YFE-based subunit vaccines expressed in <jats:italic>N. benthamiana<\/jats:italic>. However, their efficacy is inferior to that of the live attenuated 17DD vaccine, indicating that formulation development, such as incorporating a more suitable adjuvant, may be required for product development.<\/jats:p>","DOI":"10.4269\/ajtmh.16-0293","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T07:00:43Z","timestamp":1513062043000},"page":"420-431","source":"Crossref","is-referenced-by-count":36,"title":["Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models"],"prefix":"10.4269","volume":"98","author":[{"given":"Stephen","family":"Tottey","sequence":"first","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Shoji","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Mark","family":"Jones","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Chichester","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Green","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Musiychuk","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxin","family":"Si","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodanka D.","family":"Manceva","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Rhee","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moneim","family":"Shamloul","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey","family":"Norikane","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosane C.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Caride","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea N. M. R.","family":"Silva","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisol","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia C. C.","family":"Neves","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Marchevsky","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos S.","family":"Freire","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia em Imunobiol\u00f3gicos, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Streatfield","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidadi","family":"Yusibov","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"year":"2016","author":"WHO","key":"b1"},{"year":"2017","author":"WHO","key":"b2"},{"year":"2016","series-title":"Yellow Fever Vaccine YF-VAX\u00ae","author":"Sanofi Pasteur","key":"b3"},{"key":"b4","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow fever in Angola and beyond\u2014the problem of vaccine supply and demand","volume":"375","author":"Barrett","year":"2016"},{"key":"b5","series-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013"},{"key":"b6","series-title":"Cad Saude Publica","first-page":"482","article-title":"Yellow fever and public health in Brazil","volume":"24","author":"Camacho","year":"2008"},{"key":"b7","series-title":"BMC Infect Dis","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1471-2334-14-391","article-title":"Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline","volume":"14","author":"Campi-Azevedo","year":"2014"},{"key":"b8","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1016\/j.vaccine.2014.05.003","article-title":"Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil","volume":"32","author":"Martins Rde","year":"2014"},{"key":"b9","series-title":"Expert Rev Vaccines","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012"},{"key":"b10","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014"},{"first-page":"1153","year":"2007","author":"Gubler","key":"b11"},{"key":"b12","series-title":"Microbes Infect","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.micinf.2010.09.005","article-title":"Molecular mechanisms involved in the early steps of flavivirus cell entry","volume":"13","author":"Kaufmann","year":"2011"},{"key":"b13","series-title":"Viruses","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/v3020160","article-title":"Flavivirus cell entry and membrane fusion","volume":"3","author":"Smit","year":"2011"},{"key":"b14","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1099\/vir.0.82210-0","article-title":"Flavivirus membrane fusion","volume":"87","author":"Stiasny","year":"2006"},{"key":"b15","series-title":"Amino Acids","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00726-009-0370-4","article-title":"Molecular mechanisms of flavivirus membrane fusion","volume":"41","author":"Stiasny","year":"2011"},{"key":"b16","series-title":"Expert Rev Mol Med","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1017\/S1462399408000665","article-title":"Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection","volume":"10","author":"Pierson","year":"2008"},{"key":"b17","series-title":"Cell Host Microbe","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.chom.2008.08.004","article-title":"Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development","volume":"4","author":"Pierson","year":"2008"},{"key":"b18","series-title":"Ann Inst Pasteur Virol","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0769-2617(88)80006-6","article-title":"Expression of the yellow fever virus envelope protein using hybrid SV40\/yellow fever viruses","volume":"139","author":"Despr\u00e8s","year":"1988"},{"key":"b19","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1099\/0022-1317-72-6-1331","article-title":"Characterization of yellow fever virus proteins E and NS1 expressed in Vero and Spodoptera frugiperda cells","volume":"72","author":"Despr\u00e8s","year":"1991"},{"key":"b20","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1128\/jvi.63.10.4199-4209.1989","article-title":"Processing of yellow fever virus polyprotein: role of cellular proteases in maturation of the structural proteins","volume":"63","author":"Ruiz-Linares","year":"1989"},{"key":"b21","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1099\/0022-1317-72-6-1451","article-title":"17D yellow fever vaccine virus envelope protein expressed by recombinant baculovirus is antigenically indistinguishable from authentic viral protein","volume":"72","author":"Shiu","year":"1991"},{"key":"b22","series-title":"Virol J","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1743-422X-8-261","article-title":"Yellow fever virus envelope protein expressed in insect cells is capable of syncytium formation in lepidopteran cells and could be used for immunodetection of YFV in human sera","volume":"8","author":"Barros","year":"2011"},{"key":"b23","series-title":"Biologicals","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.biologicals.2008.09.001","article-title":"Plants as biofactories","volume":"36","author":"Mett","year":"2008"},{"key":"b24","series-title":"Plant Biotechnol J","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1467-7652.2010.00507.x","article-title":"Plant-made vaccines for humans and animals","volume":"8","author":"Rybicki","year":"2010"},{"key":"b25","series-title":"Hum Vaccin","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4161\/hv.7.3.14207","article-title":"Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond","volume":"7","author":"Yusibov","year":"2011"},{"key":"b26","series-title":"Curr Opin Plant Biol","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.pbi.2004.01.015","article-title":"Posttranslational modification of therapeutic proteins in plants","volume":"7","author":"Gomord","year":"2004"},{"key":"b27","series-title":"Curr Pharm Des","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.2174\/1381612811319310006","article-title":"N-glycosylation of plant-produced recombinant proteins","volume":"19","author":"Bosch","year":"2013"},{"key":"b28","series-title":"Plant Biotechnol J","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1467-7652.2009.00497.x","article-title":"Plant-specific glycosylation patterns in the context of therapeutic protein production","volume":"8","author":"Gomord","year":"2010"},{"key":"b29","series-title":"Biotechnol Adv","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.biotechadv.2011.07.015","article-title":"Post-translational modification of plant-made foreign proteins; glycosylation and beyond","volume":"30","author":"Webster","year":"2012"},{"key":"b30","series-title":"Plant Biotechnol J","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1467-7652.2012.00694.x","article-title":"Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F","volume":"10","author":"Mamedov","year":"2012"},{"key":"b31","series-title":"Plant Biotechnol J","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher\u2019s disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007"},{"key":"b32","series-title":"Am J Health Syst Pharm","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2146\/news120041","article-title":"Taliglucerase alfa approved for Gaucher disease","volume":"69","author":"Traynor","year":"2012"},{"key":"b33","series-title":"Curr Pharm Des","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.2174\/13816128113199990335","article-title":"Hybrid viral vectors for vaccine and antibody production in plants","volume":"19","author":"Yusibov","year":"2013"},{"key":"b34","series-title":"Expert Rev Vaccines","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1586\/14760584.7.8.1173","article-title":"Recent progress in the development of plant derived vaccines","volume":"7","author":"Yusibov","year":"2008"},{"key":"b35","series-title":"Influenza Other Respir Viruses","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1750-2659.2006.00005.x","article-title":"A launch vector for the production of vaccine antigens in plants","volume":"1","author":"Musiychuk","year":"2007"},{"key":"b36","series-title":"Hum Vaccin","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4161\/hv.7.0.14561","article-title":"Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza","volume":"7","author":"Shoji","year":"2011"},{"key":"b37","series-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4161\/hv.23233","article-title":"A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores","volume":"9","author":"Chichester","year":"2013"},{"key":"b38","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1016\/j.vaccine.2009.01.050","article-title":"A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague","volume":"27","author":"Chichester","year":"2009"},{"key":"b39","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1016\/j.vaccine.2007.01.017","article-title":"A plant-produced plague vaccine candidate confers protection to monkeys","volume":"25","author":"Mett","year":"2007"},{"key":"b40","series-title":"Hum Vaccin","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4161\/hv.7.0.14588","article-title":"Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity","volume":"7","author":"Farrance","year":"2011"},{"key":"b41","series-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4161\/hv.34366","article-title":"A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses","volume":"11","author":"Jones","year":"2015"},{"key":"b42","series-title":"Am J Trop Med Hyg","first-page":"206","article-title":"Tubulin-based vaccine candidates to combat African animal trypanosomiasis","volume":"83","author":"Knapp","year":"2010"},{"key":"b43","series-title":"Viruses","first-page":"3227","article-title":"Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A\/Indonesia\/05\/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults","volume":"4","author":"Chichester","year":"2012"},{"key":"b44","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.vaccine.2013.10.017","article-title":"Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults","volume":"32","author":"Cummings","year":"2014"},{"key":"b45","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1016\/j.vaccine.2007.01.068","article-title":"Immunogenicity of a subunit vaccine against Bacillus anthracis","volume":"25","author":"Chichester","year":"2007"},{"key":"b46","series-title":"Influenza Other Respir Viruses","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1750-2659.2008.00037.x","article-title":"A plant-produced influenza subunit vaccine protects ferrets against virus challenge","volume":"2","author":"Mett","year":"2008"},{"key":"b47","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.vaccine.2008.11.108","article-title":"Plant-derived hemagglutinin protects ferrets against challenge infection with the A\/Indonesia\/05\/05 strain of avian influenza","volume":"27","author":"Shoji","year":"2009"},{"key":"b48","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1016\/j.vaccine.2008.03.045","article-title":"Plant-expressed HA as a seasonal influenza vaccine candidate","volume":"26","author":"Shoji","year":"2008"},{"key":"b49","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.vaccine.2009.01.051","article-title":"Immunogenicity of hemagglutinin from A\/Bar-headed Goose\/Qinghai\/1A\/05 and A\/Anhui\/1\/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants","volume":"27","author":"Shoji","year":"2009"},{"key":"b50","series-title":"J Vis Exp","first-page":"e51204","article-title":"Optimization and utilization of Agrobacterium-mediated transient protein production in Nicotiana","volume":"86","author":"Shamloul","year":"2014"},{"key":"b51","series-title":"Protein Sci","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/pro.5560041120","article-title":"How to measure and predict the molar absorption coefficient of a protein","volume":"4","author":"Pace","year":"1995"},{"key":"b52","series-title":"Trop Med Int Health","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999"},{"key":"b53","series-title":"Biologicals","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","article-title":"Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies","volume":"40","author":"Simoes","year":"2012"},{"key":"b54","series-title":"Virus Res","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-1702(01)00273-8","article-title":"Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses","volume":"79","author":"Caufour","year":"2001"},{"key":"b55","series-title":"An Acad Bras Cienc","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1590\/S0001-37652008000200009","article-title":"Limited replication of yellow fever 17DD and 17D-dengue recombinant viruses in rhesus monkeys","volume":"80","author":"Trindade","year":"2008"},{"key":"b56","series-title":"Braz J Med Biol Res","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1590\/S0100-879X2009005000039","article-title":"Pattern of functional antibody activity against Haemophilus influenzae type B (Hib) in infants immunized with diphtheria-tetanus-pertussis\/Hib Brazilian combination vaccine","volume":"42","author":"Matos","year":"2009"},{"key":"b57","series-title":"Cytokine","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cyto.2008.02.007","article-title":"Detection of Th1\/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay","volume":"42","author":"Santos","year":"2008"},{"key":"b58","series-title":"Virology","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.virol.2010.12.020","article-title":"Antibody-mediated neutralization of flaviviruses: a reductionist view","volume":"411","author":"Dowd","year":"2011"},{"key":"b59","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010"},{"key":"b60","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.1128\/IAI.70.12.6638-6645.2002","article-title":"Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB\/c and C57BL\/6 mice","volume":"70","author":"Liu","year":"2002"},{"key":"b61","series-title":"Am J Pathol","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2353\/ajpath.2008.070776","article-title":"Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis","volume":"172","author":"Schulte","year":"2008"},{"key":"b62","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e34145","DOI":"10.1371\/journal.pone.0034145","article-title":"Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis","volume":"7","author":"Stiasny","year":"2012"},{"key":"b63","series-title":"PLoS Negl Trop Dis","doi-asserted-by":"publisher","first-page":"e2274","DOI":"10.1371\/journal.pntd.0002274","article-title":"Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans","volume":"7","author":"Puschnik","year":"2013"},{"key":"b64","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1084\/jem.20051352","article-title":"Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes","volume":"202","author":"Barba-Spaeth","year":"2005"},{"key":"b65","series-title":"J Infect Dis","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jir439","article-title":"Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody","volume":"204","author":"Luiza-Silva","year":"2011"},{"key":"b66","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1084\/jem.20051720","article-title":"Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity","volume":"203","author":"Querec","year":"2006"},{"key":"b67","series-title":"Eur J Immunol","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/eji.201142306","article-title":"The early cellular signatures of protective immunity induced by live viral vaccination","volume":"42","author":"Kohler","year":"2012"},{"key":"b68","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.1016\/j.vaccine.2010.09.090","article-title":"CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-gamma at 5\u20137 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses","volume":"28","author":"Neves","year":"2010"},{"key":"b69","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e81953","DOI":"10.1371\/journal.pone.0081953","article-title":"Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses","volume":"8","author":"Neves","year":"2013"},{"key":"b70","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1128\/JVI.75.5.2107-2118.2001","article-title":"Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes","volume":"75","author":"Liu","year":"2001"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/98\/2\/article-p420.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/98\/2\/article-p420.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/98\/2\/article-p420.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T23:03:34Z","timestamp":1722467014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/98\/2\/article-p420.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":70,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.16-0293","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}